Review: Evidence on the effectiveness of sodium bicarbonate regimens to prevent contrast-induced nephropathy is unclear
- RenalGuard fluid delivery device inhibits CIN. // Reactions Weekly;11/6/2010, Issue 1326, p4
The article two trials which aimed to investigate whether the intravenous administration of sodium bicarbonate was more effective that normal saline in preventing contrast-induced nephropathy in patients undergoing elective coronary or peripheral procedures.
- Prevention of Contrast-Induced Nephropathy With Sodium Bicarbonate: A Randomized Controlled Trial. Merten, Gregory J.; Burgess, W. Patrick; Gray, Lee V.; Holleman, Jeremiah H.; Roush, Timothy S.; Kowalchuk, Glen J.; Bersin, Robert M.; Van Moore, Arl; Simonton III, Charles A.; Rittase, Robert A.; Norton, H. James; Kennedy, Thomas P. // JAMA: Journal of the American Medical Association;5/19/2004, Vol. 291 Issue 19, p2328
Context Contrast-induced nephropathy remains a common complication of radiographic procedures. Pretreatment with sodium bicarbonate is more protective than sodium chloride in animal models of acute ischemic renal failure. Acute renal failure from both ischemia and contrast are postulated to...
- Effect of sodium bicarbonate on aspirin-induced damage and potential difference changes in human gastric mucosa. Bowen, Bruce K.; Krause, William J.; Ivey, Kevin J. // British Medical Journal;10/22/1977, Vol. 2 Issue 6094, p1052
Examines the effect of sodium bicarbonate on aspirin-induced damage. Changes in human gastric mucosa; Use of isotonic solutions in intragastric installation; Monitoring of gastric transmucosal potential differences.
- Sodium bicarbonate for prevention of contrast-induced acute kidney injury: a systematic review and meta-analysis. Hoste, Eric A. J.; De Waele, Jan J.; Gevaert, Sofie A.; Uchino, Shigehiko; Kellum, John A. // Nephrology Dialysis Transplantation;Mar2010, Vol. 25 Issue 3, p747
Background. There have been conflicting reports on the use of intravenous administration of sodium bicarbonate for prevention of contrast-induced acute kidney injury (CI-AKI). The aim of this study was to evaluate the use of sodium bicarbonate for prevention of CI-AKI.
- Are we infusing acids into our patient's blood? Mohinder Singh, Preet; Borle, Anuradha; Trikha, Anjan; Rosival, Viktor // Indian Journal of Critical Care Medicine;Jan2014, Vol. 18 Issue 1, p49
A letter to the editor and a reply are presented in response to the article "Are we infusing acids into our patients' blood?" in the previous issue of the journal.
- NICE-recommended clinical trial due to start on MIST. // Journal of Wound Care;Oct2012, Vol. 21 Issue 10, p511
The article discusses that National Institute for Health and Clinical Excellence (NICE) medical technology guidance recommended clinical trial will start soon on the MIST Therapy system to promote wound healing in chronic and acute wounds.
- Increasing evidence base for sodium bicarbonate therapy to prevent contrast media-induced acute kidney injury: little role of unpublished studies. Wiedermann, Christian J.; Joannidis, Michael // Nephrology Dialysis Transplantation;Mar2010, Vol. 25 Issue 3, p650
The article presents information on a study related to sodium bicarbonate therapy to prevent contrast media-induced acute kidney injury (CI-AKI). The researchers had made a comprehensive meta-analysis including a total of 18 trials focusing on separate analysis of papers both published and...
- The role of angiotensin receptor blockers in the prevention of cardiovascular and renal disease: time for reassessment? Fuchs, Flávio Danni // Evidence Based Medicine;Apr2013, Vol. 18 Issue 2, p44
Angiotensin receptor blockers (ARB) have been recommended as a first option for the management of hypertension by guidelines, particularly in patients at high cardiovascular risk. The preference for ARB in these conditions is based on their neutral metabolic effects, and on direct cardiac and...
- InVasc Initiates Phase IIa Proof of Concept Study with INV-144 in Patients with Chronic Kidney Disease. // Biomedical Market Newsletter;6/30/2011, p132
The article reports on the Phase IIa and proof of concept (POC) with INV-44 study initiated by InVasc Therapeutics Inc. to slow the progression of chronic kidney disease (CKD) in hypertensive diabetic patients. The study will compare the treatment of patients with losartan alone versus losartan...